University of Crete (UOC)
Μελέτη των μηχανισμών αναιμίας με έμφαση στις διαταραχές της ομοιόστασης του σιδήρου και της ερυθροποίησης σε ασθενείς με ιδιοπαθείς φλεγμονώδεις εντερικές νόσους
Abstract
dc:description1. Inflammatory Bowel Diseases (IBD). IBD is a group of diseases characterized by chronic, relapsing destructive inflammation of the gastrointestinal tract. The clinical presentation includes a variety of symptoms such as chronic or recurrent diarrhea, often with mixture of blood, abdominal pain, fever and anemia. Moreover, not infrequently symptoms are accompanied by extraintestinal manifestations of the skin (pyoderma gangrenosum, erythema nodosum), joints (arthralgia, peripheral arthritis, spondylitis) or eye (iridocyclitis, uveitis). IBD can be divided into two main forms: Crohn’s Disease (CD) and Ulcerative Colitis (UC). In the West, the incidence and prevalence of IBD has increased in the past 50 years, up to 8-14/100,000 and 120-200/100,000 persons, respectively, for UC and 6-15/100,000 and 50-200/100,000 persons, respectively, for CD¹ . Family history is an important risk factor for IBD onset, with peak incidence in early adult period of life, although individuals of all ages can be affected. IBD are considered to be the result of a continuous, excessive inflammatory response to symbiotic bacteria, in a genetically predisposed host²,³. The first genome-wide association studies in IBD were published 10 years ago and since then many areas of genetic predisposition have been found on chromosomes 1, 3, 4, 5, 6, 7, 10, 12, 14, 16, 19 and X. Hugot et al.⁴ first announced in 1996 a correlation with chromosome 16q and five years later, the underlying gene CARD15 (or NOD2) was identified. More recently, over one year, seven genome-wide association studies have been published, and many additional genes for CD and UC have been identified (ATG16L1, IL23R, PTGER4, IRGM, NELL1). Data from immunological, microbiological and genetic studies favor an impaired interaction between host and microbes in the pathogenesis of IBD⁵. Microbial aberrations observed in patients with IBD, with consequent disruption of the intestinal flora, may be due to colonization by enteric pathogens, to host inflammatory response or to combination⁶. Furthermore, recent data, concerning pathogenesis of IBD, support the hypothesis of a significant interaction among 3 fundamental biological pathways of the cell: autophagy, microbial sensing and endoplasmic reticulum stress⁷. Other factors that play an important role in the pathogenesis of IBD are hypoxia, metabolic factors⁸, inflammatory cytokines⁹, and disorders of homeostasis regulation¹⁰. 2. Anemia of IBD. Anemia is one of the most common extraintestinal manifestations of IBD, with a strong impact on quality of life. According to the World Health Organization (WHO), anemia is defined as hemoglobin level below 120 g/L in women and 130 g/L in men, at sea level. The main cause of anemia in IBD patients is iron deficiency due to chronic blood loss and decreased absorption of iron from the intestinal mucosa, due to inflammation. However, anemia in IBD appears to have a multifactorial etiology, and frequently appears as the result of a combination of iron deficiency (most common cause) and anemia of inflammation or anemia of chronic disease (second most common cause). Iron deficiency takes place when loss of iron exceeds the amount of iron absorbed from the intestine. This situation of negative iron balance occurs when not enough iron is consumed, when iron absorption is suspended, when body requirements in iron are increased (e.g. during pregnancy or puberty) or due to iron loss, because of bleeding/blood loss. The main cause of iron deficiency is blood loss from the urogenital system in women or the gastrointestinal tract in both sexes. The anemia of IBD is mainly due to iron deficiency. Many of the above pathogenetic mechanisms play a role in the development of iron deficit in IBD. Another factor that influences the absorption of food iron is increased levels of hepcidin (as a result of chronic inflammation), leading to reduced outflow of iron from enterocytes. However, chronic blood loss from ulcerated intestinal mucosa remains the main cause of negative iron balance in IBD¹¹ . Anemia of chronic disease (ACD) seems to be the result of stimulation of the immune system from the underlying process and specific inflammatory cytokines, including tumor necrosis factor-alpha (TNFα), interferon-γ (IFNγ) and interleukin (IL)-1, 6, 8 and 10. So far, 3 main pathophysiological factors, underlying ACD, have been identified. All are induced by stimulation of the intrinsic immune mechanism: First, inflammation leads to iron retention within cells of the reticuloendothelial system, resulting in limited availability of iron for erythropoietic progenitor cells. Secondly, proliferation and differentiation of erythropoietic progenitor cells are down-regulated by cytokines and acute phase proteins. Thirdly, reduced production and biological activity of endogenous EPO induces development of ACD. Briefly, in ACD, several different pathophysiological mechanisms (corresponding cytokines) seem to be involved¹²,¹³: 1. Reduced life span of erythrocytes due to dyserythropoiesis, increased destruction rate and increased phagocytosis (TNFα). 2. Poor response of EPO production, for the corresponding degree of anemia, in many but not all patients (IL-1 & TNFα). 3. Decreased sensitivity of erythroid cells against EPO stimulation (IFNγ, IL-1, TNFα, hepcidin). 4. Inhibition of maturation and differentiation of erythroid cells (IFNγ, IL-1, TNFα, alpha1-antitrypsin). 5. Abnormal iron homeostasis due to increased expression of DMT1 (IFNγ) and TfR (IL-10) in macrophages, decreased expression of ferroportin 1 (elevated hepcidin concentration due to IFNγ and IL-6) in enterocytes (inhibition of iron absorption) and macrophages (suspension of iron recirculation), and increased rate of ferritin synthesis (TNFα, IL-1, IL-6, IL-10) (increased iron storage). Diagnostic approach to anemia in IBD, particularly concerning distinguish of iron deficiency anemia (IDA) from ACD, includes many well established and new generation laboratory markers, which, in combination, may diagnose the degree of involvement of each type of anemia, with great accuracy. Ferritin, with transferrin saturation and CRP, is the minimum group of tests required for IBD patients with anemia. The combination of serum ferritin and soluble transferrin receptor (sTfR) levels, can be used to identify iron deficiency (high sTfR, low ferritin), inflammation (normal sTfR and ferritin) or mixed states (increased sTfR, normal ferritin). Moreover, ferritin levels <30 micrograms/L (in combination with transferring saturation <16%) is an established marker of iron deficiency, in patients with inflammation. In the presence of inflammation, the lower limit of serum ferritin, which corresponds to normal iron stores, is 100 μg/L, so that diagnostic criteria for ACD is serum ferritin >100 μg/L and transferring saturation <16%. When ferritin levels are between 30 and 100 μg/L, a combination of true IDA and ACD is probable. Finally, serum ferritin can be used in the form of sTfR/log ferritin ratio, as a useful tool for IDA exclusion, when it is <1¹⁴. Iron metabolism regulators, hepcidin and prohepcidin, are under evaluation and it seems to play a central role in the development of anemia in IBD, but are rather inadequate to separate IDA from ACD. In addition, a variety of red cell and reticulocyte indices play a supporting role in the diagnosis of anemia in IBD, are still under evaluation, whereas some of them seem to reflect different pathophysiological mechanisms of anemia, very precisely¹⁵. Therapeutic approach to anemia in IBD involves iron replacement therapy (oral or intravenous), administration of erythropoietic agents, while recent trends include treatment of ACD. Hepcidin antagonists are expected to help patients with disorders of over-expression of this hormone, presented as IDA, on a basis of ACD¹⁶. 3. Clinical studies. The aims of clinical studies in this thesis were: 1. The survey of epidemiological, clinical and laboratory data on anemia in patients with IBD, who are monitored in the Gastroenterology Clinic at University Hospital of Heraklion. 2. The investigation of iron homeostasis disorders and their correlation with the mechanisms of inflammation in patients with IBD, with particular emphasis on the role of the protein hepcidin. 3. The investigation of erythropoiesis disorders in patients with IBD, with emphasis on the role of conventional and new generation blood markers in the diagnosis of erythropoiesis and iron homeostasis disorders. 4. The investigation of the effects of therapeutic interventions in the above mechanisms and parameters. …
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Oustamanolakis, Panteleimon
- Ουσταμανωλάκης, Παντελεήμων
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27375